Medios AG

Ladies and gentlemen, welcome to the earnings call of MEDIUS AG for the first nine months of 2025. At our customer's request, this conference will be recorded. As a reminder, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. If any participant has difficulties hearing the conference, please press zero followed by the hash key for operator assistance. May I now hand you over to Claudia Nicolaus, Head of Investor and Public Relations and ESG Communications at Meteos. Please go ahead.

Welcome everybody to our earnings call for the first nine months of 2025. As always, all relevant documents can also be downloaded from our investor relations website. Additionally, this presentation can be followed in parallel via the internet link provided to you in the invitation. Today with me is our CEO, Matthias Gärtner, and our CFO, Falk Neukirch. Matthias will start with an executive summary, followed by Falk, who will then provide details on the financials of the first nine months and the guidance for 2025. After the presentation, we will begin the Q&A session. I would now like to hand over to Matthias.

Okay, thank you, Claudia. Ladies and gentlemen, welcome to our conference call for the first nine months of 2025. We continue to see solid growth, which is reflected in strong financials for the first nine months of 2025. We posted record revenues for the third quarter as well as for the first nine months of 2025, driven by organic and inorganic growth. With Thomas Mayer, we could announce our new CEO as of February 26. I'm very confident that he, together with my executive board colleagues and the entire team of meteors, will lead our company into the next decade of growth, success, and market leadership. Back to the highlights and achievements in the first nine months of 25 on slide three. We had a very good year so far, and I'm proud of the progress we made. Again, we posted very solid financials. Revenue grew by 9.2% to 1.5 billion euros. All segments contributed to revenue and earnings growth, meaning both organic and inorganic. EBITDA-free rose disproportionately by 26.1%, to 70.4 million euros. Consequently, EBITDA pre-margin rose from 4.0 to 4.6%. I would especially like to highlight the solid organic earnings growth of 5.1%. This is in line with our guidance assumption of organic growth in the mid-single-digit percentage range. Furthermore, EPS increased by 84% to 79 cents and EPS, the chart grew by almost 26% to 1.5 Euro. Also, the operating cash flow was strong, up 90% compared to last year. All in all, we have once again succeeded in our ambition to increase our overall profitability. This confirms the operational strength of our company and our strategy, which is focused on increasing margins while maintaining growth. Based on these results, we fully confirm our guidance for the year 2025. Falk will provide more insight into the financials later. Our international activities strongly support our European platform, and make us a leading player in the specialty pharma compounding in Europe. This network is an excellent basis for our further international expansion, the realization of synergies and cross-selling opportunities. Furthermore, it will support the development of our activities in the field of advanced therapies, the future of individualized medicine. As outlined at our last earnings call, we successfully conducted a share buyback of 1 million Meteos shares, representing 3.92% of our current share capital. Another good news was that since October 16, we are back in the SDAGs. Also in October, we welcomed Janus Henderson as a new major shareholder in Meteos, with a stake of around 6.4%. They bought all the shares from Bensys Capital. And since November 4, we have a new analyst coverage by Montega, with a buy recommendation and a target price of 24 euros. Slide 4 shows the quarter-on-quarter development of our two KPIs, revenue and EBITDA pre-evaluation. There are fluctuations between the various quarters. In 23 and 24, we saw very strong third quarters due to the special effects the inflation-related price increases. Even without this effect, Q3-25 revenue was on a record level. EBITDA-3, however, was slightly below Q3-24. Falk will come back to this later. Now the same illustration for the first nine months shown on slide five. Whereas revenue for the first nine months, 25, increased by 9.2%, EBITDA pregrew even stronger by more than 26% compared to the first nine months of 24. As already mentioned, this is in line with our strategy to further focus on profitability. Let's move to slide six. with some comments on our activities in the field of advanced therapies. We are establishing a stronger presence in this new field of activities that is predicted to reach a double digit growth rate in the future. Currently, our focus is on the subfield of personalized cancer vaccines. These vaccines have the potential to replace conventional cancer therapies and even to cure cancer. Manufacturing these new vaccines require high expertise in the area of small-scale fill and finish. This expertise already exists within the Mateos networks. Before I hand over to Falk, I would like to thank everyone who participated in the perception study conducted in September. We received valuable feedback that we will consider, in particular with regard to our investor relations work. This is all for now from my side. Now, Falk will provide more details on the financials for the first nine months of 2025 and the guidance for 2025.